表紙
市場調查報告書

惡性間皮癌治療藥的全球市場:2019年∼2023年

Global Malignant Mesothelioma Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 891089
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
惡性間皮癌治療藥的全球市場:2019年∼2023年 Global Malignant Mesothelioma Therapeutics Market 2019-2023
出版日期: 2019年07月16日內容資訊: 英文 125 Pages
簡介

惡性間皮癌,是侵犯覆蓋肺、胸牆,及腹部的間皮薄組織的稀少形態的癌症。全球惡性間皮癌治療藥市場,2018年化療市場區隔佔大幅市場佔有率,預計這個趨勢在預測期間內也將持續。對化療需求增加等要素,將在化療市場區隔中發揮重要作用。還有全球惡性間皮癌治療藥市場,由於在聯合治療的採用的增加,商業目的的石棉使用增加,及特別的法規指定等要素,在預測期間內將以約7%的年複合成長率擴大。然而,惡性間皮癌的長潛伏期,初期階段的疾病專一生物標記的缺乏,及癌症治療的先進設備的開發、核准等要素,可能妨礙預測期間的惡性間皮癌治療產業的成長。

本報告提供惡性間皮癌治療藥全球市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 化療
  • 其他的治療藥物
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 惡性間皮癌的認識高漲
  • 新治療方法的開發
  • 化療的償付政策

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31697

About this market

A malignant mesothelioma is a rare form of cancer affecting the thin tissue known as mesothelium that lines the lung, chest wall, and abdomen. Technavio's malignant mesothelioma therapeutics market analysis considers sales from both chemotherapy and other therapeutics. Our analysis also considers the sales of malignant mesothelioma therapeutics in Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing demand for chemotherapy will play a significant role in the chemotherapy segment to maintain its market position. Also, our global malignant mesothelioma therapeutics report also looks at factors such as increasing adoption of combination therapies, increasing use of asbestos for commercial purposes, and special regulatory designations. However, a long latency period of malignant mesothelioma, lack of disease-specific biomarkers in earlier stages, and development and approval of advanced devices for cancer treatment may hamper the growth of the malignant mesothelioma therapeutics industry over the forecast period.

Overview

Increasing the use of asbestos for commercial purposes

Exposure to asbestos is the primary risk factor for malignant mesothelioma. The significant rise in the use of asbestos in commercial purposes such as building materials, machines, and transport vehicles is causing this disease in the workers due to regular exposure. The extensive use of asbestos for commercial purpose will lead to the expansion of the global malignant mesothelioma therapeutics market at a CAGR of almost 7% during the forecast period.

Increasing awareness of malignant mesothelioma

The increasing incidence and prevalence of malignant mesothelioma across the world leading to an increasing need for awareness initiatives to diagnose and treat the disease at earlier stages. Many organizations are spreading awareness about the disease and advising workers who are regularly exposed to asbestos to undergo regular screening of malignant mesothelioma, which may prevent the disease progression to advanced stages. This increasing awareness is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global malignant mesothelioma therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global malignant mesothelioma therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading malignant mesothelioma therapeutics companies, that include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.

Also, the malignant mesothelioma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing awareness of malignant mesothelioma
  • Development of novel therapies
  • Reimbursement policies for chemotherapy

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in North America
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Europe
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Drug designations
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 49: Bristol-Myers Squibb Co. - Product segments
  • Exhibit 50: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 51: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 52: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 53: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 54: Eli Lilly and Co. - Vendor overview
  • Exhibit 55: Eli Lilly and Co. - Business segments
  • Exhibit 56: Eli Lilly and Co. - Organizational developments
  • Exhibit 57: Eli Lilly and Co. - Geographic focus
  • Exhibit 58: Eli Lilly and Co. - Segment focus
  • Exhibit 59: Eli Lilly and Co. - Key offerings
  • Exhibit 60: Eli Lilly and Co. - Key customers
  • Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 68: Merck & Co. Inc. - Vendor overview
  • Exhibit 69: Merck & Co. Inc. - Business segments
  • Exhibit 70: Merck & Co. Inc. - Organizational developments
  • Exhibit 71: Merck & Co. Inc. - Geographic focus
  • Exhibit 72: Merck & Co. Inc. - Segment focus
  • Exhibit 73: Merck & Co. Inc. - Key offerings
  • Exhibit 74: Merck & Co. Inc. - Key customers
  • Exhibit 75: Pfizer Inc. - Vendor overview
  • Exhibit 76: Pfizer Inc. - Business segments
  • Exhibit 77: Pfizer Inc. - Organizational developments
  • Exhibit 78: Pfizer Inc. - Geographic focus
  • Exhibit 79: Pfizer Inc. - Segment focus
  • Exhibit 80: Pfizer Inc. - Key offerings
  • Exhibit 81: Pfizer Inc. - Key customers
  • Exhibit 82: Validation techniques employed for market sizing
  • Exhibit 83: Definition of market positioning of vendors